Aurélie Le Gal MD , Ambroise Marçais MD, PhD , Céline Goyard MD , Anne-Laure Brun MD , Morgane Cheminant MD, PhD , Nizar Mahlaoui MD, PhD , Claire Givel MD , Colas Tcherakian MD, PhD , Alexandre Chabrol MD , Frédéric Wallyn MD , Leonardo Magro MD , Flore Sicre de Fontbrune MD , Regis Peffault de la Tour MD, PhD , Abdellatif Tazi MD, PhD , Amira Benattia MD , Remi Valter MD , Philippe Devillier MD, PhD , Louis-Jean Couderc MD, PhD , Felipe Suarez MD, PhD , Emilie Catherinot MD, PhD , Hélène Salvator MD, PhD
{"title":"异基因造血干细胞移植对先天性免疫缺陷成人肺部并发症的影响。","authors":"Aurélie Le Gal MD , Ambroise Marçais MD, PhD , Céline Goyard MD , Anne-Laure Brun MD , Morgane Cheminant MD, PhD , Nizar Mahlaoui MD, PhD , Claire Givel MD , Colas Tcherakian MD, PhD , Alexandre Chabrol MD , Frédéric Wallyn MD , Leonardo Magro MD , Flore Sicre de Fontbrune MD , Regis Peffault de la Tour MD, PhD , Abdellatif Tazi MD, PhD , Amira Benattia MD , Remi Valter MD , Philippe Devillier MD, PhD , Louis-Jean Couderc MD, PhD , Felipe Suarez MD, PhD , Emilie Catherinot MD, PhD , Hélène Salvator MD, PhD","doi":"10.1016/j.jaci.2025.04.032","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Pulmonary involvement (repeated lung infections, lung parenchymal inflammation, scarring, and malignancies) is frequent in patients with inborn errors of immunity (IEIs) and accounts for a significant proportion of the disease burden. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can cure most severe IEIs. The indications for allo-HSCT have recently been extended to adults.</div></div><div><h3>Objective</h3><div>We sought to assess the impact of allo-HSCT specifically on respiratory status.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed data of 50 patients with IEIs who underwent a first allo-HSCT after the age of 16 at 3 expert centers in France.</div></div><div><h3>Results</h3><div>The median length of follow-up was 4.8 years (interquartile range: 1.6-9.2) before allo-HSCT and 3 years (interquartile range: 1.4-6.0) after allo-HSCT. Ten patients died as a result of allo-HSCT–related complications. Four patients developed bronchiolitis obliterans syndrome. After 1-year posttransplantation, the mean annualized rate of severe respiratory infections (0.14 [95% CI: 0.04 to 0.24]) was lower than the value recorded before transplantation (0.54 [95% CI: 0.25 to 0.82]; <em>P</em> = .003 for paired comparisons of equivalent durations). Lung function was declining before allo-HSCT (mean FEV<sub>1</sub>: −2.09% predicted/year [95% CI: −7.27 to 3.09]) but increased afterward (+2.44% predicted/year [95% CI: −4.79 to 9.69], <em>P</em> = .0034 for paired comparisons). On computed tomography scans of the chest, bronchial disorders and lung parenchyma cavities were the most frequent abnormal findings. The bronchial thickening and bronchiolar micronodules regressed after allo-HSCT, whereas bronchiectasis and residual parenchymal cavities were stable.</div></div><div><h3>Conclusions</h3><div>allo-HSCT seems likely to protect the long-term pulmonary prognosis of adults with IEIs; it is associated with a significantly lower incidence of severe respiratory infections, better lung function, and radiologic stabilization of lung damage.</div></div>","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":"156 3","pages":"Pages 825-834"},"PeriodicalIF":11.2000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The impact of allogeneic hematopoietic stem cell transplantation on pulmonary complications in adults with inborn errors of immunity\",\"authors\":\"Aurélie Le Gal MD , Ambroise Marçais MD, PhD , Céline Goyard MD , Anne-Laure Brun MD , Morgane Cheminant MD, PhD , Nizar Mahlaoui MD, PhD , Claire Givel MD , Colas Tcherakian MD, PhD , Alexandre Chabrol MD , Frédéric Wallyn MD , Leonardo Magro MD , Flore Sicre de Fontbrune MD , Regis Peffault de la Tour MD, PhD , Abdellatif Tazi MD, PhD , Amira Benattia MD , Remi Valter MD , Philippe Devillier MD, PhD , Louis-Jean Couderc MD, PhD , Felipe Suarez MD, PhD , Emilie Catherinot MD, PhD , Hélène Salvator MD, PhD\",\"doi\":\"10.1016/j.jaci.2025.04.032\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Pulmonary involvement (repeated lung infections, lung parenchymal inflammation, scarring, and malignancies) is frequent in patients with inborn errors of immunity (IEIs) and accounts for a significant proportion of the disease burden. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can cure most severe IEIs. The indications for allo-HSCT have recently been extended to adults.</div></div><div><h3>Objective</h3><div>We sought to assess the impact of allo-HSCT specifically on respiratory status.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed data of 50 patients with IEIs who underwent a first allo-HSCT after the age of 16 at 3 expert centers in France.</div></div><div><h3>Results</h3><div>The median length of follow-up was 4.8 years (interquartile range: 1.6-9.2) before allo-HSCT and 3 years (interquartile range: 1.4-6.0) after allo-HSCT. Ten patients died as a result of allo-HSCT–related complications. Four patients developed bronchiolitis obliterans syndrome. After 1-year posttransplantation, the mean annualized rate of severe respiratory infections (0.14 [95% CI: 0.04 to 0.24]) was lower than the value recorded before transplantation (0.54 [95% CI: 0.25 to 0.82]; <em>P</em> = .003 for paired comparisons of equivalent durations). Lung function was declining before allo-HSCT (mean FEV<sub>1</sub>: −2.09% predicted/year [95% CI: −7.27 to 3.09]) but increased afterward (+2.44% predicted/year [95% CI: −4.79 to 9.69], <em>P</em> = .0034 for paired comparisons). On computed tomography scans of the chest, bronchial disorders and lung parenchyma cavities were the most frequent abnormal findings. The bronchial thickening and bronchiolar micronodules regressed after allo-HSCT, whereas bronchiectasis and residual parenchymal cavities were stable.</div></div><div><h3>Conclusions</h3><div>allo-HSCT seems likely to protect the long-term pulmonary prognosis of adults with IEIs; it is associated with a significantly lower incidence of severe respiratory infections, better lung function, and radiologic stabilization of lung damage.</div></div>\",\"PeriodicalId\":14936,\"journal\":{\"name\":\"Journal of Allergy and Clinical Immunology\",\"volume\":\"156 3\",\"pages\":\"Pages 825-834\"},\"PeriodicalIF\":11.2000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Allergy and Clinical Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0091674925005160\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0091674925005160","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
The impact of allogeneic hematopoietic stem cell transplantation on pulmonary complications in adults with inborn errors of immunity
Background
Pulmonary involvement (repeated lung infections, lung parenchymal inflammation, scarring, and malignancies) is frequent in patients with inborn errors of immunity (IEIs) and accounts for a significant proportion of the disease burden. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can cure most severe IEIs. The indications for allo-HSCT have recently been extended to adults.
Objective
We sought to assess the impact of allo-HSCT specifically on respiratory status.
Methods
We retrospectively analyzed data of 50 patients with IEIs who underwent a first allo-HSCT after the age of 16 at 3 expert centers in France.
Results
The median length of follow-up was 4.8 years (interquartile range: 1.6-9.2) before allo-HSCT and 3 years (interquartile range: 1.4-6.0) after allo-HSCT. Ten patients died as a result of allo-HSCT–related complications. Four patients developed bronchiolitis obliterans syndrome. After 1-year posttransplantation, the mean annualized rate of severe respiratory infections (0.14 [95% CI: 0.04 to 0.24]) was lower than the value recorded before transplantation (0.54 [95% CI: 0.25 to 0.82]; P = .003 for paired comparisons of equivalent durations). Lung function was declining before allo-HSCT (mean FEV1: −2.09% predicted/year [95% CI: −7.27 to 3.09]) but increased afterward (+2.44% predicted/year [95% CI: −4.79 to 9.69], P = .0034 for paired comparisons). On computed tomography scans of the chest, bronchial disorders and lung parenchyma cavities were the most frequent abnormal findings. The bronchial thickening and bronchiolar micronodules regressed after allo-HSCT, whereas bronchiectasis and residual parenchymal cavities were stable.
Conclusions
allo-HSCT seems likely to protect the long-term pulmonary prognosis of adults with IEIs; it is associated with a significantly lower incidence of severe respiratory infections, better lung function, and radiologic stabilization of lung damage.
期刊介绍:
The Journal of Allergy and Clinical Immunology is a prestigious publication that features groundbreaking research in the fields of Allergy, Asthma, and Immunology. This influential journal publishes high-impact research papers that explore various topics, including asthma, food allergy, allergic rhinitis, atopic dermatitis, primary immune deficiencies, occupational and environmental allergy, and other allergic and immunologic diseases. The articles not only report on clinical trials and mechanistic studies but also provide insights into novel therapies, underlying mechanisms, and important discoveries that contribute to our understanding of these diseases. By sharing this valuable information, the journal aims to enhance the diagnosis and management of patients in the future.